



Supplementary Figure 1. Schematic of reprogramming cassette and a map of


pCAG2LMKOSimO vector. **a.** The four reprogramming factors are translated from a single mRNA encoding *c-Myc*, *Klf4*, *Oct4* and *Sox2* linked with three different 2A sequences, *F2A*, *T2A* and *E2A*. The sequences of the 2A peptides and their 'skip' sites are shown. **b.** *c-Myc*, *Klf4*, *Oct4* and *Sox2* coding regions linked by three different 2A peptide sequences, *F2A*, *T2A* and *E2A* (reprogramming cassette) are transcribed from the CAG enhancer/promoter. The reprogramming cassette is followed by *ires mOrange*. The reprogramming cassette and *ires mOrange* are flanked by *loxP* sites. pCAG2LMKOSimO is linearized with PvuI before transfection.




Supplementary Figure 2. Robust expression of reprogramming factors using a multiprotein expression vector. **a.** Immunoblot analysis of nuclear extracts of HEK293 cells 48 hrs post transfection with pCAGMKOSiE (293+MKOS). Nuclear extract of ES cells (ES) and HEK293 cells without nucleofection (293) are used to identify exogenous protein expression. An anti- α tubulin antibody is used as a loading control. **b.** Immunoblot analysis for phospho-T58 c-Myc in HEK293 with (293+MKOS) and without transfection (293). **c.** Immunofluorescence of HEK293 cells for Oct4 and Sox2 24 hrs post transfection of pCAGMKOSiE. ES cells and HEK293 cells provide positive and negative controls, respectively.




Supplementary Figure 3. Reprogramming with pCAG2LMKOSimO and estimation of stable transfection efficiency in MEF using nucleofection. a. mOrange positive ES cell like-colonies picked 20-30 days post nucleofection successfully grew on a gelatin-coated culture dish. **b.** TNG MEFs (top row) or non-genetically modified 129 MEFs (bottom two rows) were seeded on irradiated MEFs (γ MEF) or gelatin (Gelatin) after nucleofection. Pictures represent Nanog-EGFP positive colonies from TNG MEFs and Nanog positive colonies (immunofluorescence) from 129 MEFs (green) with mOrange expression (red) 28 days post transfection. **c.** A vector that derives EGFP expression via the CAG enhancer/promoter was introduced into MEFs and the percentage of EGFP positive cells was monitored by FACS for 20 days after nucleofection without selection. The gray and black lines represent two independent experiments. Averages of EGFP positive cells were 86% and 3% of total cells at day 2 and day 20, respectively. We estimate stable integration occurred in 3.6% (3% of 86%) of transiently transfected cells.







Supplementary Figure 5. Schematic presentation of vector integration sites and expression of the genes. **a-c.** Integration sites of imO1, imO3 and imO7 were found in chromosome 5 (a), chromosome 1 (b) and chromosome 17 (c), respectively. The red box in chromosome diagrams is enlarged below with the vector integration site indicated by black lines. Primers used for validation of the integration sites in Figure 2c are shown as black arrows. Diagrams and gene abbreviations were referred from Ensemble genomic databases. **d.** Expression of the genes in the integration sites. *Mll3*, *Atf6* and *Wdr27* expression is detectable in MEFs, ES cells and iPS cell clones, imO1, imO3, imO7 by RT-PCR. Numbers in parenthesis indicate cycle number of the PCR.




Supplementary Figure 7. Differentiation induced by Cre-mediated excision of the reprogramming cassette. **a.** Flat differentiated colonies with no mOrange expression and tight three-dimensional colonies with mOrange expression appeared seven days after *Cre* transfection. **b.** Diagram of the vector before and after Cre-mediated excision. Arrows indicates primers used to validate excision had occurred. **c.** Examples of genomic PCR before and after reprogramming cassette excision. Data represent one of the clones (imO2c and imO7c) generated from the cell lines, imO2 and imO7, respectively, by *Cre* transfection.



Supplementary Figure 8. Expression of reprogramming factors and pluripotent markers after Cre-excision. **a.** Quantitative PCR for total *c-Myc*, *Klf4*, *Oct4* and *Sox2* expression before (imO2E1, imO3, imO7; black) and after (imO2Ec3, imO3c8, imO7c8; gray) reprogramming cassette excision. Data is shown as relative expression to an ES cell line, E14Tg2a (E14). Error bars indicate the s.d. generated from triplicates. **b.** Quantitative PCR for pluripotency markers. Data represents one of two independent experiments.



Supplementary Figure 9. Efficient differentiation of reprogramming cassette-free iPS cell lines *in vitro*. **a.** Embryoid body (EB) differentiation. Cre-treated cell lines, imO2Ec3, imO3c8 and imO7c8 EBs showed similar down-regulation of pluripotent markers (*Oct4*, *Nanog*, *Rex1*), and up-regulation of endoderm (*Gata6*), ectoderm (*Fgf5*) and mesoderm (*Brachyury*, *Flk1*) markers to that of ES cells, while their parental cell lines, imO2E1, imO3 and imO7, differentiated less efficiently. Note up-regulation of *Fgf5* and *Brachyury* is transient in the EB differentiation. **b.** *In vitro* neural differentiation. Reprogramming cassette excised iPS cells, imO3c8, differentiated into β -tubulin positive neurons (green in left panels) as efficient as ES cells after 7 days in neural differentiation conditions. The parental iPS cell line, imO3, with an intact reprogramming cassette hardly generated neurons and maintained Oct4 expression (green in right panels).



Supplementary Figure 10. Non-viral reprogramming of human embryonic fibroblast with a single-vector reprogramming system combined with PiggyBac transposon. **a.** The structure of two PB transposons containing (i) a tetO promoter-driven 2A sequence-joint four reprogramming factors (MKOS) followed by *β-geo* (top), and (ii) CAG enhancer/promoter-driven *rtTA* (bottom). **b.** Three clones, hiPSC117, hiPSC121 and hiPSC122, maintaining undifferentiated human ES cell-like morphology after withdrawal of doxycycline (Dox) (top panels). LacZ activity was hardly detectable in the absence of Dox in all three cell lines, suggesting the undifferentiated state of the cell lines was exogenous factors independent (middle and bottom panels). **c.** Expression of endogenous pluripotency markers (SSEA4, NANOG, TRA-160 and TRA-181) was observed in all three cell lines. Data shown from one of the cell lines, hiPSC122.

Supplementary Table 1. Estimation of reprogramming efficiency (%)

	Experiment No.	No. of expected stable transfectants ¹	Efficiency ²	
			γ MEF	Gelatin
TNG	1	295	-	2.03
	2	168	-	2.09
129	1	227	-	1.54
	2	134	4.48	1.49
	3	187	4.27	0.53
	4	216	3.24	2.78

1. Cell numbers which were expected to obtain stable integration were estimated from mOrange positive cell number at day 2 in Table 1, and stable transfection efficiency (3.6% of transient transfected cells as estimated in Supplementary Figure 2)
2. Reprogramming efficiency was estimated using the number of expected stable transfectants¹ and that of Nanog-GFP/Nanog positive colonies in Table 1. – indicates no data.

Supplementary Table 2. Summary of blastocyst injections

cell line	No. of transferred embryos	Chimeric embryos ¹					Pups	Live chimera (Chimerism ²)
		8.5 dpc	9.5 dpc	10.5 dpc	11.5 dpc	12.5 dpc		
imO7c8	52	-	-	-	-	-	28	5 (+++, +, +, +, +)
imO1c5	31	-	-	-	-	-	15	1 (+)
imO7Ec3	22	-	-	-	4/8	-	0	0
imO7Ec3+PD ³	62	-	-	-	-	6/10	0	0
imO3c8	40	-	-	-	-	-	10	0
ImO3c8+PD ³	39	-	-	-	-	-	8	0
imO3Ec5	39	-	-	-	-	-	10	0
imO3Ec5+PD ³	96	8/10	7/8	4/5	-	6/8	12	1 (+)

¹ Number of GFP positive chimeric embryos / total embryos at indicated stages. -; not examined. Most of the chimeric embryos had high contribution as shown in Figure 3F.

² Chimerism was judged by coat color. +++ > 80%, + 10-30%.

³ Cells were cultured in the presence of PD173074 for more than one week before injection. In other cases without the indication, cells were cultured for more than one week in the absence of PD173074.

Supplementary Table 3. Primers used for vector construction**Reprogramming cassette**

EcoRI Koz 5'-Myc	gaattcaccatgccctcaacgtgaactt
Myc-3' GSG F2A	tccacgtctcccgccaacttgagaaggtcaaaattcaaagtctgtttcacgccagaac ctgcaccagagtttcgaagct
F2A 5'-Klf4	cttgaatttgaccttctcaagttggcgaggagacgtggagtccaacccagggcccatga ggcagccacctggc
Klf4-3' GSG T2A Xho	ctcgagtgggccaggattctcctcgacgtcaccgcatgtagcagacttcctctgcct ctccggagccaaagtgcctcttcatgtgta
Xho 5'-Oct4	ctcgagatggctggacacctggcttc
Oct4-3' GSG E2A	ttactttcaacatcgccagcagagtttcaacaaagcgtagttagtacattgacccgacc cgtttgaatgcatgggagagc
E2A 5'-Sox2	actacgctttgttgaaactcgctggcgatgttgaaagtaaccccggtcctatgtataa catgatggagac
Sox2-3' EcoRI Xho	ctcgagaattctcacatgtgcgacaggggca

loxP oligo

Kpn Bam loxP BamX F	cggatccataacttcgtatagcatacattatacgaagttatc
Kpn Bam loxP BamX R	gatcgataacttcgtataatgtatgctatacgaagttatggatccggtac

ires mOrange

Not IRES	gcggccgccccctctccctcccccccccta
mOrange IRES	tgctcaccatgggttgcccatattatcat
IRES mOrange	ggccacaaccatgggtgagcaagggcgagga
Xba Bam loxP mOrange	agtctagaggatccataacttcgtataatgtatgctatacgaagttatctactgtac agctcgtccatg

Supplementary Table 4. Primers used for inverse PCR and Cre-mediated excision test

Inverse PCR

invAluF	gctgagtagtgcgcgagcaaa
invAluR1	gcgacacggaaatggtgaata
invAluR2	gccgcatagttaagccagtat
inv3TaqF1	tatctcagttcggtgtaggtcg
inv3TaqR	aagataccaggcggttcccc

Integration site validation

Forward		Reverse	
imO1 5'	tttttctcagggtgtgccag	invAluR2	gccgcatagttaagccagtat
		imO1 3'	ctcaaaccttcacagtgcc
imO3 5'	tgccgctccacaaatattga	invAluR1	gcgacacggaaatggtgaata
		imO3 3'	ggaggcatataaagcaatggc
imO7 5'	gggtactggaattggagctc	invAluR2	gccgcatagttaagccagtat
		imO7 3'	accatcattagtcagctcccct

Concatemer test

Forward		Reverse	
inv3TaqF1	tatctcagttcggtgtaggtcg	invAluR2	gccgcatagttaagccagtat

Cre-mediated excision test

Forward		Reverse	
CAG F	ctctgctaaccatgttcatgc	BGH R	tagaaggcacagtcgagg
IRESmOrange	ggccacaaccatggtgagcaagggcgagga		

Supplementary Table 5. Gene specific primers

Quantitative PCR

Genes	Forward	Reverse
Total		
<i>c-Myc</i>	MycT F cctagtgcgcatgaggaga	MycT R tcttcctcatcttcttgccttc
<i>Klf4</i>	Klf4T F cggaaggagagaagacact	Klf4T R gagttcctcacgccaacg
<i>Oct4</i>	Oct4T F gttgagaaggtggaacaa	Oct4T R ctccttgcagggttcttc
<i>Sox2</i>	Sox2T F acagctacgcgcacatga	Sox2T R ggtagcccagctgctcct

Endogenous

<i>c-Myc</i>	c-Myc F tcaagcagacgagcacaagc	c-Myc R tacagtcccaaagcccagc
<i>Klf4</i>	Klf4 F ggcgagaaaccttaccactgt	Klf4 R tactgaactctctcctggca
<i>Oct4</i>	Oct4-906F ccaacgagaagagtatgaggc	Oct4UTR R gtgcttttaatccctcctcag
<i>Sox2</i>	Sox2-3 F tctgtggtcaagtccgaggc	Sox2UTR R ttctccagttcgcagtcag

<i>Ecat1</i>	Ecat1 FT ggcgagctgagatttgata	Ecat1 RT ccagcctccagagcctctat
<i>Eras</i>	Eras FT gcccctcatcagactgctac	Eras RT gcagctcaaggaagaggtgt
<i>Dppa3</i>	Dppa3 FT gatgcacaacgatccagattt	Dppa3 RT tggaattagaacgtacatactcaa
<i>Dppa4</i>	Dppa4 FT aagggtttccagaacaat	Dppa4 RT tccagaggaactgtcacctca
<i>Dppa5</i>	Dppa5 FT attcgggctaaatggatgc	Dppa5 RT tagctccaggggtcttcattg
<i>Utf1</i>	Utf1 FT gtccctctccgcgttagc	Utf1 RT ggggcaggttcgtcattt
<i>Dnmt3l</i>	Dnmt3l FT caactaccgcttccttcag	Dnmt3l RT cccgcatagcattctggta
<i>Tcl1</i>	Tcl1F gcttctctctgggtgttca	Tcl1R cccacacattcccttcaac
<i>Klf2</i>	Klf2 F ctaaaggcgcacatgcgta	Klf2 R tagtggcgggtaagctcgt
<i>Rex1</i>	Rex1F ggaagaaatgctgaaggtggagac	Rex1R agtcccatcccttcaatagc
<i>Gbx2</i>	Gbx2 F gtgctcgtttctctgc	Gbx2 R gtgtaatccacatcgtctc
<i>Esrrb</i>	Esrrb F tggcaggcaaggatgacaga	Esrrb R tttcatgagggccgtggga
<i>Nanog</i>	NanogQT F cctccagcagatgcaagaa	NanogQT R gcttgcaactcatcctttgg
<i>Tbp</i>	Tbp FT ggggagctgtgatgtgaagt	Tbp RT ccaggaaataattctggctca

Embryoid body PCR

Genes	Forward	Reverse
<i>Oct4</i>	Oct4 F ccaacgagaagagtatgaggc	Oct4 R agagcagtgacgggaacagag
<i>Nanog</i>	Nanog F gtgcataactctctccttccc	Nanog R agctaccctcaaactcctggt
<i>Rex1</i>	Rex1 F ggaagaaatgctgaaggtggagac	Rex1 R agtcccatcccttcaatagc

<i>Fgf5</i>	Fgf5 F2	ttgcgacccaggagettaat	Fgf5 R2	ctacgcctctttattgcage
<i>Brachyury</i>	T F2	ccaaggacagagagacggct	T R2	agtaggcattgtccaagggc
<i>Gata6</i>	Gata6 F	cccacttctgtgttccaattg	Gata6 R	ttggtcacgtggtacaggcg
<i>Flk1</i>	Flk1 F	gcttgetccttcctcatctc	Flk1 R	ccatcaggaagccacaaagc
<i>Gapdh</i>	Gapdh F	gtgttcctaccccaatgtg	Gapdh R	gtcattgagagcaatgccag

Supplementary Methods

Cell culture and blastocyst injection

MEFs from 13.5-14.5 dpc 129 mice embryos were generated following a standard method. To isolate fibroblasts from adult mouse footpads, finely chopped footpad skin of 6-8 weeks old 129 mice were incubated in 0.25% trypsin, 1mM EDTA, 100 µg/ml DNase in PBS at 37 °C. After 15 minutes the trypsin solution was collected into a tube with GMEM containing 10% FCS through a fine mesh to remove debris. The skin was trypsinized two more times in the same way. All isolated cells were combined and cultured in GMEM containing 10% FCS, penicillin/streptomycin, L-glutamine, β-mercaptoethanol, non-essential amino acids, and human basic FGF (10 ng/ml). The footpad fibroblasts (FPFs) were used for experiments within 4-8 passages. MEFs from C57BL/6 strain TNG mice²³ (TNG MEFs) were kindly provided by I. Chambers. MEFs and HEK293 cells were cultured in the same medium as for FPFs without basic FGF. Leukemia inhibiting factor (LIF) (1,000 U/ml) was added for iPS cell derivation and maintenance. ES cell-like colonies derived from 129 MEFs were picked 4 weeks after nucleofection, trypsinised with 0.25% trypsin, 0.1% EDTA in PBS, and seeded on γMEFs or directly on gelatin in 4 well plates as the first passage. A wild type ES cell line, E14Tg2a, and established iPS cells were passaged on gelatin-coated dishes every 2-3 days. Cell lines, imO2Ec3, imO3Ec5 and imO7Ec3, were generated by excising the reprogramming cassette from imO2E1, imO3E1 and imO7E1, respectively, which has randomly integrated CAG-EGFP cassette. Embryoid body formation and neural differentiation was performed and the resulting cells were used for RT-PCR and immunofluorescence as described before^{26,27}. Chimeras were produced by microinjection into C57BL/6 blastocysts. Chimerism of embryos was analyzed at 8.5-12.5 dpc by observing GFP expression. Genital ridges from 12.5 dpc embryos were stained with anti-Oct4 antibody (N-19, Santa Cruz) and observed with a confocal microscope (Leica TSC SP2). Cre-treated cell lines were cultured for more than one week in the absence of PD173074 before RNA extraction, teratoma formation assay and blastocyst injections.

Immunoblotting

Nuclear extracts were prepared as described before²⁶. Transfected HEK293 cells were harvested 48 hrs post transfection. Antibodies against c-Myc (N-262), Klf4 (H-180) Oct4 (N-19), Sox2 (Y-17) and α-tubulin (B-7) were purchased from Santa Cruz, and an anti-phospho-T58 c-Myc antibody (ab28842) was purchased from Abcam.

Inverse PCR

Genomic DNA extracted from imO1, imO3, and imO7 was digested with AluI, SpeI or TaqI.

After self-ligation for 18 hours at 16 °C, the DNA was used as PCR templates for primers in Supplementary Table 4. Amplified fragments were purified, cloned into pCRII-TOPO vector (Invitrogen) and sequenced. The integration sites of imO1 and imO7 were identified with invAluF/invAluR2 primers in AluI digested genome and SpeI digested genome, respectively. The integration site of imO3 was identified with invAluF/invAluR1 primers in AluI digested genome. inv3TaqF1/inv3TaqR primers identified concatemers in the TaqI-digested imO1 and imO3 genomes. The integration site and concatemer were verified using specific primers listed in Supplementary Table 4.

Bisulfite sequencing

Bisulfite conversion was performed using Imprint DNA Modification Kit (Sigma) following manufacturer's instruction. The promoter regions of Oct4 and Nanog are amplified with specific primers¹, and the products were cloned into pCRII-TOPO vector (Invitrogen). Ten randomly chosen clones were sequenced from each cell line for each gene.

Human embryonic fibroblast (HEF) isolation

Twelve week-old abortion material washed in PBS, macerated and treated thrice with TrypLE, 0.1% EDTA. The suspension was plated on untreated dishes in HEF media (DMEM, 15% human serum, 10 ng/ml bFGF, penicillin-streptomycin, glutamax, β -mercaptoethanol, non-essential amino acids) and grown for 3 days at 37 °C, 5% CO₂. Then the primary cells were passaged once for expansion and frozen in aliquots (p2).

PB transfection and cell culture

HEFs were grown to 90% confluency (36-48 hrs at 37°C, 5% CO₂) and seeded at a density of 3.2 and 6.4x10⁴ cells/10 cm² in 6-well plates containing HEF medium (DMEM, 15% human serum, 10 ng/ml bFGF, penicillin-streptomycin, glutamax, β -mercaptoethanol, non-essential amino acids). After 18-24 hrs growth, the cells were transfected with 100 ng or 250 ng of transposon delivering the 2A sequence linked reprogramming factors, the PB embedded CAG-rtTA-pA cassette and 100 ng of pCyL43 PB transposase plasmid¹⁵ (normalized to 2 μ g total DNA with empty pBluescriptKS+). To generate transfection complexes 2 μ g total DNA was diluted to 100 μ l with DMEM, mixed with FugeneHD (Roche) at a Fugene:DNA ratio of 8 μ l:2 μ g, incubated at room temperature for 15-20 min, and added to the media. 24 hours post-transfection 1.5 mg/ml doxycycline was added to the medium and kept for 32 days. 48 hrs post-transfection the HEF medium was changed to ES medium (HEScGRO). Cells were fed daily until analyzed. Colonies were picked and passaged using mechanical dissociation.